Nucs AI Launches TrackPSMA for Prostate Cancer Care
Slice of Healthcare Team
11/26/2025
Key highlights
- AI-driven solution for assessing treatment response
- Leverages PSMA-PET/CT scans for improved accuracy
- Helps identify quick treatment modifications
- Enables lesion-by-lesion tracking for precision
- Reduces manual analysis, improving clinician workflows
Source: PR Newswire
Notable Quotes
“ For the first time, we can measure therapy response objectively and reproducibly across scans, sites, and timepoints. ”
Farid Yagubbayli, CTO at Nucs AI
“ TrackPSMA also represents a critical step forward in applying AI to RLT treatment planning. ”
Nijat Ahmadov, CEO at Nucs AI
Why this matters
The launch of TrackPSMA marks a significant advancement in prostate cancer care by providing an automated, standardized method for evaluating treatment responses, addressing a critical gap in identifying effective therapies and enhancing patient care. This innovative AI solution stands to transform treatment protocols, improving outcomes while also streamlining workflows for clinicians. This development is particularly significant for the healthcare sector.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
